Ross Fubini - Jun 13, 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Stock Option	Award	$0	+1.11M	$0.00	1.11M	Jun 13, 2024	Class A Common Stock	1.11M	$0.46	Direct	F1, F2
transaction	DNA	Stock Option	Award	$0	+571K	$0.00	571K	Jun 13, 2024	Class A Common Stock	571K	$0.46	Direct	F3, F4
transaction	DNA	Restricted Stock Units	Award	$0	+433K	$0.00	433K	Jun 13, 2024	Class A Common Stock	433K	$0.00	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the initial option award as of the grant date is $400,000.
F2	The initial stock options shall vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, such that the initial stock options shall be fully vested on the third anniversary of the date of grant, subject to the Reporting Person continuing in service as a Non-Employee Director through such date.
F3	In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the additional initial option award as of the grant date is $200,000.
F4	The vesting date of the RSUs and additional initial options, and in the case of the additional initial options, the exercise date, will be the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date.
F5	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.